E156: The Future of Clinical Trials, $18m Series A and Breaking Bottlenecks - Meri Beckwith (Co-founder Lindus Health)

In this week’s episode, Meri shares his journey from the world of investing to breaking the bottlenecks in clinical trials as he builds the anti-CRO for life science pioneers. 

We discussed: 

🔄 Transitioning from venture capital into healthtech 
💼 Investor vs Founder Traits, Personality and Mindset
🌱 The origin story of Lindus Health 
🏗️ The first few days/weeks of building Lindus Health 
🚧 Barriers to entering the pharma industry as a new startup
🔒 Securing the first clinical trial with Habitual
🍾 The bottle necks of clinical trials
🔍 The process of recruiting patients for clinical trials
❌ Where central organisations and institutions go wrong for clinical trials
🤖 The role of AI in the pharma industry 
💰 Fundraising a $18m Series A with investments from the likes of Peter Thiel 
🔒 How to prevent being replaced by the board and investors 
🏢 How to build a healthy culture and team 
🤝 How to become a great CEO and deal with co-founder conflicts
💊 Why do pharma need CROs for clinical trials and why become the anti-CRO

Meri Beckwith is the co-founder of Lindus Health and previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw trail outcomes could be improved by focusing on patient experience. 

 

-------------------------------------

Powered by  Peerr

Peerr is a healthtech platform connecting the health and life sciences industry through content and thought leaders, KOLs and SMEs.

✍️ Publish articles or blogs, courses or offer coaching services

🗒 Over 250,000+ reads and 500+ articles

 

www.peerr.io

-------------------------------------

 

YouTube:Amz & Abdul

Twitter -@ScrubbedIn_
Instagram - @Scrubbedin_

Follow us on Instagram & Twitter

Hello@scrubbedin.co.uk